A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary purpose of this study is to help answer the following research questions, and not to provide treatment for diabetes :

* The safety of LY2409021 and any side effects that might be associated with it following 4 weeks of doses
* How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks
* How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other naturally occurring substances before and after a meal
* How LY2409021 works when given with metformin
* How daily dosing of LY2409021 affects the cells that produce insulin

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes

NCT01606371

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of LY2608204 in Patients With Type 2 Diabetes

NCT01247363

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients

NCT01253278

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of Multiple Doses of LY2922470 in Participants With Diabetes

NCT01867216

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of LY3305677 in Participants With Type 2 Diabetes

NCT03928379

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo administered orally once daily for 4 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally (capsule)

5 mg LY2409021

5 mg LY2409021 administered orally once daily for 4 weeks

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally (capsule)

30 mg LY2409021

30 mg LY2409021 administered orally once daily for 4 weeks

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally (capsule)

60 mg LY2409021

60 mg LY2409021 administered orally once daily for 4 weeks

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally (capsule)

90 mg LY2409021

90 mg LY2409021 administered orally once daily for 4 weeks

Group Type EXPERIMENTAL

LY2409021

Intervention Type DRUG

Administered orally (capsule)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Administered orally (capsule)

Intervention Type DRUG

LY2409021

Administered orally (capsule)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be either a male, or a female who cannot become pregnant, who has type 2 diabetes and is either controlling diabetes through diet and exercise, or taking metformin
* Have an hemoglobin A1c (HbA1c) value at screening of greater than or equal to 6.5% and less than or equal to 10.0% on a stable treatment regimen at the time of measurement
* Have a screening body mass index (BMI) of 20 to 40 kg/m\^2 inclusive
* Have a blood pressure reading at screening of between 90 to 160 millimeters of mercury (mmHg) (systolic) and 40 to 95 mmHg (diastolic)

Exclusion Criteria

* Have used insulin for diabetic control within 1 year of study entry
* Have used thiazolidinediones within 3 months, or any other drugs for treatment of hyperglycemia (except metformin) within 1 month, prior to first planned dosing. Metformin is acceptable for this study.
* Have clinically significant coronary artery disease
* Have clinically significant peripheral vascular disease
* Have clinical evidence of active diabetic proliferative retinopathy
* Have known significant autonomic neuropathy as evidenced by urinary retention, orthostatic hypotension, diabetic diarrhea or gastroparesis
* Impaired renal function (serum creatinine greater than 115 micromoles/liter \[μmol/L\] \[1.3 mg/dL\] in women, greater than 130 μmol/L \[1.5 mg/dL\] in men)
* Have triglycerides greater than 4.5 millimoles per liter (mmol/L) \[approximately 400 mg/dL\] at screening
* Were hospitalized for poor control of diabetes (keto-acidotic episode) in the last 6 months
* Are allergic to LY2409021 or similar drugs
* Have history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (other than diabetes), hematological, or neurological disorders capable of significantly altering the absorption, or metabolism or elimination of drugs or of constituting a risk when taking the study medication or interfering with the interpretation of data
* Have used systemic glucocorticoids within 1 month prior to first dosing
* Have donated 450 mL or more of blood in the last 3 months or have donated any blood within the last month
* Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female), or are unwilling to stop alcohol as required by the study restrictions (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits)

Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No